64 related articles for article (PubMed ID: 2575914)
1. Mutual activation of glutamatergic mGlu
Cieślik P; Woźniak M; Rook JM; Tantawy MN; Conn PJ; Acher F; Tokarski K; Kusek M; Pilc A; Wierońska JM
Psychopharmacology (Berl); 2018 Oct; 235(10):2897-2913. PubMed ID: 30054675
[TBL] [Abstract][Full Text] [Related]
2. Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.
Rossi G; Frediani S; Rossi R; Rossi A
BMC Psychiatry; 2012 Aug; 12():122. PubMed ID: 22909285
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine in the treatment of schizophrenia : an open label comparative clinical trial from north India.
Avasthi A; Kulhara P; Kakkar N
Indian J Psychiatry; 2001 Jul; 43(3):257-63. PubMed ID: 21407865
[TBL] [Abstract][Full Text] [Related]
4. Amisulpride: a review of its use in the management of schizophrenia.
Curran MP; Perry CM
Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
[TBL] [Abstract][Full Text] [Related]
5. Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.
Stip E
J Psychiatry Neurosci; 2000 Mar; 25(2):137-53. PubMed ID: 10740987
[TBL] [Abstract][Full Text] [Related]
6. A risk-benefit assessment of sulpiride in the treatment of schizophrenia.
Mauri MC; Bravin S; Bitetto A; Rudelli R; Invernizzi G
Drug Saf; 1996 May; 14(5):288-98. PubMed ID: 8800626
[TBL] [Abstract][Full Text] [Related]
7. Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia.
Möller HJ; van Praag HM; Aufdembrinke B; Bailey P; Barnes TR; Beck J; Bentsen H; Eich FX; Farrow L; Fleischhacker WW
Psychopharmacology (Berl); 1994 Jun; 115(1-2):221-8. PubMed ID: 7862898
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors.
Corbett R; Camacho F; Woods AT; Kerman LL; Fishkin RJ; Brooks K; Dunn RW
Psychopharmacology (Berl); 1995 Jul; 120(1):67-74. PubMed ID: 7480537
[TBL] [Abstract][Full Text] [Related]
9. The treatment of negative symptoms: pharmacological and methodological issues.
Carpenter WT
Br J Psychiatry Suppl; 1996 May; (29):17-22. PubMed ID: 8733819
[No Abstract] [Full Text] [Related]
10. Do negative symptoms respond to pharmacological treatment?
Kane JM; Mayerhoff D
Br J Psychiatry Suppl; 1989 Nov; (7):115-8. PubMed ID: 2575914
[No Abstract] [Full Text] [Related]
11. [Depressive symptoms in schizophrenia].
Gerard A
Encephale; 1998 Jul; 24 Spec No 1():24-6. PubMed ID: 9809250
[No Abstract] [Full Text] [Related]
12. [Effect of neuroleptics on depressive symptoms].
Tabeze JP
Encephale; 1998 Jul; 24 Spec No 1():38-41. PubMed ID: 9809254
[No Abstract] [Full Text] [Related]
13. [Clozapine and treatment of negative symptoms].
Lançon C; Farisse J; Llorca PM
Encephale; 1997 Sep; 23 Spec No 4():7-11. PubMed ID: 9417403
[TBL] [Abstract][Full Text] [Related]
14. Simple schizophrenia in an adolescent.
Valentí M; Castro-Fornieles J; Lázaro ML; Sugrañes G; Baeza I
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):589-90. PubMed ID: 19877985
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
